publication date: Oct. 4, 2019
NCI Trials for October
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
For further information, contact the principal investigator listed.
Phase I – ABTC-1804
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas
Adult Brain Tumor Consortium
Grossman, Stuart Alan
Phase II – ACNS1723
A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG) (IND# 145355)
Children’s Oncology Group
Lulla, Rishi Ramesh
Phase III – A221803
Mepitel Film for the Reduction of Radiation Dermatitis in Breast Cancer Patients Undergoing Post-Mastectomy Radiation Therapy: A Randomized Phase III Clinical Trial
Alliance for Clinical Trials in Oncology
Corbin, Kimberly S.
Phase Other – WF-1805CD
Implementation and Effectiveness Trial of HN-STAR
Wake Forest NCORP Research Base
Weaver, Kathryn E.